CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 1.12: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.58%Below 5Y avg (1.23%)
Annual Rate
CNY 0.05Paid annual
Payout Ratio
750.0%High
Last Ex-Dividend
Sep 11, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
3.80BCNY566.95M · vs all stocks (USD)
Trailing P/E
215.75xRevenue (TTM)
2.46BCNY367.69M · vs all stocks (USD)
Profit Margin
0.85%Beta
0.4180xvs all stocks
52-Week Change
-20.48%vs all stocks
Market Capitalization
3.80BCNY566.95M · vs all stocks (USD)
Enterprise Value
6.40BCNY956.24M · vs all stocks (USD)
Trailing P/E
215.75xForward P/E
13.92xPrice to Sales (TTM)
1.54xPrice to Book (MRQ)
1.53xEnterprise to Revenue
2.60xEnterprise to EBITDA
19.18xGross Margin
17.98%Profit Margin
0.85%Operating Margin
2.07%Return on Assets (TTM)
0.92%Return on Equity (TTM)
0.81%Revenue (TTM)
2.46BCNY367.69M · vs all stocks (USD)
Revenue per Share (TTM)
4.69CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-1.20%Gross Profit (TTM)
468.80MCNY70.01M · vs all stocks (USD)
EBITDA (TTM)
168.29MCNY25.13M · vs all stocks (USD)
Net Income (TTM)
21.02MCNY3.14M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.30%Operating Cash Flow (TTM)
-12.46MCNY-1.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-244.38MCNY-36.49M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0500CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.58%vs all stocks
5-Year Average Dividend Yield
1.23%vs all stocks
Payout Ratio
750.00%Minority Interest (Equity)
6.34MCNYFY2025 · Dec 31, 2025Revenue
2.45BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.94BCNYFY2025 · Dec 31, 2025Gross Profit
503.59MCNYFY2025 · Dec 31, 2025Operating Income
137.06MCNY20.47M · vs all stocks (USD)
Pre-tax Income
7.00MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.28MCNYFY2025 · Dec 31, 2025Net Income
10.27MCNYFY2025 · Dec 31, 2025EBIT
86.13MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
377.66MCNYFY2025 · Dec 31, 2025Research & Development
128.22MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
167.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.95MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
79.13MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
511.42MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
511.42MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
10.27MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-46.10KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-273.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-540.22MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
349.39MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
10.27MCNYFY2025 · Dec 31, 2025Other Non-cash Items
64.70MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-204.63MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-144.09MCNYFY2025 · Dec 31, 2025Capital Expenditures
-266.48MCNYFY2025 · Dec 31, 2025Net Acquisitions
10.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-266.47MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.22BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.97BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-145.98MCNYFY2025 · Dec 31, 2025Other Financing Charges
49.85MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
154.08MCNYFY2025 · Dec 31, 2025Shares Outstanding
438.41MSharesUpdated Sep 22, 2026Float Shares
327.20MSharesUpdated Sep 22, 2026% Held by Insiders
19.96%vs all stocks
% Held by Institutions
4.01%vs all stocks
Total Cash (MRQ)
287.70MCNY42.96M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6560CNYUpdated Sep 22, 2026Total Debt (MRQ)
2.91BCNY434.58M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.17xCurrent Ratio (MRQ)
1.02xBook Value per Share (MRQ)
5.65CNYUpdated Sep 22, 2026Total Assets
6.16BCNY919.16M · vs all stocks (USD)
Total Current Assets
2.27BCNYFY2025 · Dec 31, 2025Total Liabilities
3.59BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.88BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
1.15BCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.44BCNYFY2025 · Dec 31, 2025Cash
349.32MCNYFY2025 · Dec 31, 2025Cash Equivalents
66.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
415.34MCNYFY2025 · Dec 31, 2025Accounts Receivable
479.86MCNYFY2025 · Dec 31, 2025Inventory
1.19BCNYFY2025 · Dec 31, 2025Accounts Payable
374.42MCNYFY2025 · Dec 31, 2025Short-term Debt
1.94BCNYFY2025 · Dec 31, 2025Other Current Liabilities
379.05KCNYFY2025 · Dec 31, 2025Long-term Debt
946.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
438.41MCNYFY2025 · Dec 31, 2025Retained Earnings
327.26MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.56BCNY382.92M · vs all stocks (USD)
52-Week Low
7.89CNYUpdated Sep 22, 202652-Week High
14.37CNYUpdated Sep 22, 202652-Week Change
-20.48%vs all stocks
Beta
0.4180xvs all stocks
50-Day MA
8.80CNYUpdated Sep 22, 2026200-Day MA
10.04CNYUpdated Sep 22, 2026Avg 10-Day Volume
5.76MSharesUpdated Sep 22, 2026Avg 30-Day Volume
6.85MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.0400CNYUpdated Sep 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 3,139,215.26Operating Cash Flow (USD, TTM): -1,860,914.621
Financial Health
Altman Z-Score 1.12: grey zoneSignificant
Altman Z-Score: 1.12
Low earnings qualitySignificant
Earnings Quality Score: -2.73
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Neurogene Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Well Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Assure Tech Hangzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Monopar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gujarat Themis Biosyn Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Hicin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemoCentryx Inc
Tier 1ProductionApproval-Gated PipelineRule